Publikationen in Zusammenarbeit mit Forschern von Hospital de Móstoles (15)

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

    Hepatology, Vol. 66, Núm. 2, pp. 344-356

2015

  1. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958

2014

  1. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287

2013

  1. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus

    Journal of Hepatology, Vol. 58, Núm. 6, pp. 1104-1112

2012

  1. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with hiv and hepatitis c virus

    Clinical Infectious Diseases, Vol. 55, Núm. 5, pp. 728-736

2011

  1. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849

2008

  1. Efectos secundarios graves derivados de las interacciones medicamentosas del tratamiento antirretroviral

    Revista Clinica Espanola, Vol. 208, Núm. 11, pp. 557-560

  2. New CCR5 inhibitor antiretroviral drugs and integrase inhibitors

    Revista Clinica Espanola, Vol. 208, Núm. 9, pp. 463-466

2005

  1. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors

    Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 5, pp. 800-804

2004

  1. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

    Vaccine, Vol. 22, Núm. 23-24, pp. 2966-2973

2002

  1. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260

  2. Tratamiento antirretroviral inicial

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, Núm. SUPPL.2, pp. 3-9

1996

  1. ESTUDIO TRANSVERSAL MULTIHOSPITALARIO DE TUBERCULOSIS Y RESISTENCIAS EN MADRID (OCTUBRE DE 1993-ABRIL DE 1994)

    Medicina Clinica, Vol. 106, Núm. 1, pp. 1-6

1989

  1. Visceral leishmaniasis (Kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in spain

    Reviews of Infectious Diseases, Vol. 11, Núm. 4, pp. 655-660